Clinical trial
SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With…
NCT00110799 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00110799 |
|---|---|
| Title | SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C |
| Official title | A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre, Dose-Ranging, Parallel Group, Phase II Study to Assess Efficacy, Safety/Tolerability, and Pharmacokinetics of a Thrombopoietin Receptor Agonist, SB-497115-GR, When Administered as 30, 50, and 75 mg Once Daily for 12 Weeks in Subjects With |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic, Thrombocytopenia |
| Intervention type | Drug, Other |
| Interventions | SB497115, Placebo |
| Enrollment | 75 |
| Start date | Apr 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | May 16, 2005 |
| Last update posted | Jun 4, 2012 |
| Countries | France, Germany, Puerto Rico, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: